Loading organizations...
§ Private Profile · Tübingen, Baden-Wurttemberg, Germany
Clinical-stage biotech company developing small-molecule drugs for sensorineural hearing loss, restoring inner ear hair cells.
Acousia Therapeutics is a clinical-stage biotechnology company developing targeted small-molecule drugs to treat acute and chronic sensorineural hearing loss, based in Tübingen, Germany. The organization focuses on pharmaceutical therapies like its lead candidate, ACOU085, which is delivered via a transtympanic slow-release gel to protect and restore sensory hair cell function in the inner ear. Operating with an estimated headcount of under 50 employees, the privately held firm has raised approximately $14.57 million in total funding to advance its ongoing clinical trials. Its venture capital backing includes a €10 million Series B financing round and strategic investments from prominent European life science funds such as Boehringer Ingelheim Venture Fund, Wellington Partners, Kurma Partners, and Creathor Ventures. Acousia Therapeutics was originally founded in 2012 by Hubert Löwenheim, Christoph R. Mueller, and EMC Microcollections GmbH.
Acousia Therapeutics has raised $14.6M across 2 funding rounds.
Acousia Therapeutics has raised $14.6M in total across 2 funding rounds.
Acousia Therapeutics has raised $14.6M in total across 2 funding rounds.
Acousia Therapeutics's investors include Harald Poth, Frank Kalkbrenner, Bregua Corporation, KfW, Boehringer Ingelheim, Stefan Lohmer.
Acousia Therapeutics has raised $14.6M across 2 funding rounds. Most recently, it raised $11.9M Series B in May 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 14, 2018 | $11.9M Series B | Harald Poth | Frank Kalkbrenner, Bregua Corporation, KFW | Announced |
| Dec 16, 2016 | $2.6M Venture Round | Boehringer Ingelheim | Stefan Lohmer, KFW | Announced |